Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
223.2 USD -1.41% Intraday chart for Penumbra, Inc. -5.58% -11.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nyrada Begins Good Laboratory Practice Preclinical Study for Brain Injury Drug Candidate MT
Truist Securities Cuts Penumbra's Price Target to $280 From $290, Keeps Buy Rating MT
Piper Sandler Adjusts Price Target on Penumbra to $290 From $310, Maintains Overweight Rating MT
North American Morning Briefing : Traders Await -2- DJ
Deutsche Bank Raises Penumbra Price Target to $288 From $257, Maintains Buy Rating MT
Truist Securities Cuts Price Target on Penumbra to $290 From $300, Maintains Buy Rating MT
Traders Await Fresh Cues After Nvidia-Fueled Rally as US Equity Futures Inch Higher Pre-Bell MT
JPMorgan Downgrades Penumbra to Neutral From Overweight, Cuts Price Target to $250 From $284 MT
Penumbra Q4 Non-GAAP EPS, Revenue Increase; Shares Fall After-Hours MT
Transcript : Penumbra, Inc., Q4 2023 Earnings Call, Feb 22, 2024
Earnings Flash (PEN) PENUMBRA Posts Q4 Revenue $284.7M, vs. Street Est of $286.5M MT
Earnings Flash (PEN) PENUMBRA Reports Q4 EPS $0.76, vs. Street Est of $0.70 MT
Penumbra, Inc. Provides Earnings Guidance for the Full Year 2024 CI
Penumbra, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
RBC Raises Price Target on Penumbra to $289 From $280, Keeps Outperform Rating MT
RBC Capital Adjusts Penumbra's Price Target to $280 From $248, Keeps Outperform Rating MT
Transcript : Penumbra, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 08:15 AM
Truist Securities Raises Price Target on Penumbra to $295 From $265, Maintains Buy Rating MT
Truist Adjusts Penumbra's Price Target to $265 From $240, Keeps Buy Rating MT
Transcript : Penumbra, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-28-2023 01:30 PM
Penumbra, Inc. Announces First Patient in STORM-PE RCT Enrolled Evaluating Penumbra's Latest Computer Assisted Vacuum Thrombectomy - Lightning Flash for Treatment of Acute Pulmonary Embolism CI
Medical device stocks rise in relief after Wegovy heart benefits data RE
Medical device makers rise on relief after Wegovy obesity trial data RE
Deutsche Bank Cuts Penumbra Price Target to $257 From $367, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on Penumbra to $240 From $265, Maintains Equalweight Rating MT
Chart Penumbra, Inc.
More charts
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
223.2 USD
Average target price
280 USD
Spread / Average Target
+25.46%
Consensus